Guidelines (National)

Information

01 October 2017

30 January 2013

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

NICE TA231. (Terminated appraisal). Surrey and Borders Partnership NHS Foundation Trust worked with the PCN prior to the terminated appraisal and reconsidered the decision made when NICE terminated the appraisal for agomelatine. The PCN members concurred that good practice guidance on managing the introduction of new healthcare interventions where NICE guidance is not available was followed by Surrey & Borders Partnership- NHS Foundation Trust and the PCN. The PCN continue to support the use of agomelatine as a treatment option for the management of depression in the following circumstances: - 2nd line where patients have not adhered to initial treatment because they have experienced side effects such as sexual dysfunction, weight gain, sleep disorders or other side effects AND- 3rd line where a patient's symptom of depression has not improved after taking at least two SSRIs or two antidepressants from different classes e.g. an SSRI and SNRI

15 August 2018

Not Set

The Mood Hive and associated local depression and anxiety treatment guidelines have been removed from PAD. Updated guidelines and resources for treating and managing depression in adults are being developed by Surrey & Borders Partnership. For current advice, in line with NICE guidance, please see the Clinical Knowledge Summaries - link provided below